Effects of micronutrient supplementation during pregnancy on birth, child health and development outcomes: a systematic review

Emily Keats, Aamer Imdad, Zulfiqar Bhutta

Submitted to the Coordinating Group of:

- [ ] Crime and Justice
- [ ] Education
- [ ] Disability
- [x] International Development
  - [x] Nutrition
- [ ] Social Welfare
- [ ] Methods
- [ ] Knowledge Translation and Implementation
- [ ] Other:

Plans to co-register:

- [ ] No
- [x] Yes [ ] Cochrane [ ] Other
- [ ] Maybe

Date submitted:
Date revision submitted:
Approval date:
Effects of micronutrient supplementation during pregnancy on birth, child health and development outcomes: a systematic review

Background

Micronutrient deficiencies are widespread among women of reproductive age (WRA) in low- and middle-income countries (LMICs) (Black, 2013), largely as a result of diets that lack diversity and thus do not provide sufficient amounts of essential vitamins and minerals (FAO & WHO, 2004). Because of increased nutritional requirements throughout pregnancy, deficiencies are often exacerbated during this time and have been associated with several adverse outcomes for both the mother and the baby (Berti, 2011; Black, 2001; Dunn, 1993; Haider, 2013; De-Regil, 2015).

To overcome the complications associated with micronutrient deficiencies during pregnancy, supplementation has been recommended as part of routine antenatal care. The World Health Organization (WHO) currently recommends iron folic acid supplementation or, in places where anaemia is a severe public health problem, iron supplementation alone (WHO, 2012). To address the issue of multiple deficiencies, the United Nations Children’s Fund (UNICEF), United Nations University (UNU), and the WHO developed a multiple-micronutrient tablet that provides the daily recommended intake of vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, vitamin B12, folic acid, vitamin C, vitamin D, vitamin E, copper, selenium, and iodine with 30mg iron and 15mg of zinc for pregnant women (UNICEF, WHO & UNU, 1999).

Results from micronutrient supplementation efficacy trials have demonstrated notable improvements for various outcomes (Haider, 2017; Hodgetts, 2015; Lassi, 2013; Pena-Rosas, 2015) and, as such, supplementation strategies have been absorbed into nutritional and antenatal care programmes in many LMICs. However, compliance can be an issue, indicating that in a real life setting pregnant women may not be gaining all the potential benefits of supplementation.

This review aims to synthesize the existing evidence on prenatal micronutrient supplementation, both from trials and existing programmes in LMICs. We will investigate a broad range of maternal and child health outcomes, including potential adverse effects, which are relevant to policy and programming in these settings. This approach will enable a comprehensive assessment of the effectiveness of micronutrient supplementation during pregnancy for improving maternal and child health, birth, and development outcomes.
Objectives

1. What is the effectiveness of iron folic acid supplementation during pregnancy on birth, child health and development outcomes?
2. What is the effectiveness of multiple micronutrient supplementation during pregnancy on birth, child health and development outcomes?
3. What is the effectiveness of single micronutrient supplementation (calcium, vitamin D, iodine) during pregnancy on birth, child health and development outcomes?
4. What is the effectiveness of lipid-based nutrient supplementation during pregnancy on birth, child health and development outcomes?

Existing reviews

**Objective 1: Iron folic acid supplementation**


**Objective 2: Multiple micronutrient supplementation**


**Objective 3: Single micronutrient supplementation**


Hodgetts VA, Morris RK, Francis A, Gardosi J, Ismail KM. Effectiveness of folic acid supplementation in pregnancy on reducing the risk of small-for-gestational age neonates: a population study, systematic review and meta-analysis. BJOG 2015;122:478–90.


**Objective 4: Lipid-based nutrient supplementation**


**Intervention**

The following interventions targeting pregnant women will be included:

- Single micronutrient supplementation (calcium, vitamin D, iodine, folic acid, vitamin A, zinc) compared to placebo or supplements without the micronutrient of interest
  - Supplementation may take the form of tablets, drops, syrup, or powder
- Iron folic acid supplementation compared to folic acid alone or placebo or supplements without iron or folic acid
- Vitamin D and calcium supplementation compared to placebo or supplements without vitamin D or calcium
- Multiple micronutrient supplementation compared to iron folic acid supplementation
  - Trials that use fewer than 3 micronutrients in the composition of the MMN supplement will be excluded
- Lipid-based nutrient supplementation compared to multiple micronutrient supplementation or placebo

**Population**

The target population is healthy (i.e. non-diseased) pregnant women of any age or parity living in low- and middle-income countries (as defined by the World Bank). As such, our review will include all women of reproductive age, including adolescent girls (10-19 years). Outcomes will pertain to both mothers and their infants, where applicable.
Outcomes

For simplification, we have split all secondary outcomes of interest by maternal, fetal, newborn, child, and other outcomes.

**Primary outcomes**
- Anemia/iron-deficiency anemia in pregnancy
- Low birth weight (<2500 g)
- Perinatal mortality (stillbirths and deaths ≤7 days)

**Secondary outcomes**

*Maternal Outcomes*

**Mortality:**
- Maternal death (death while pregnant or within 42 days of pregnancy termination)

**Morbidity:**
- Pre-eclampsia/eclampsia
- Gestational hypertension
- Antepartum haemorrhage
- Postpartum haemorrhage
- Premature rupture of membranes
- Placental abruption
- Infections during pregnancy
- Clinical malaria
- Bone mineral density
- Incidence of fracture
- Hypothyroidism
- Thyroid size
- Night blindness
- Need for blood transfusion

**Biochemical status:**
- Micronutrient deficiencies
  - Vitamin A (serum/plasma retinol)
  - Iron (serum/plasma ferritin, plasma TfR, TIBC)
  - Serum/plasma/red blood cell folate
  - Serum/plasma zinc
  - Serum/plasma vitamin D (25-hydroxyvitamin D)
- Thyroglobulin concentration

*Fetal Outcomes*

**Mortality:**
- Miscarriage (loss of pregnancy before 28 weeks gestation)
- Stillbirth (death at or beyond 28 weeks’ gestation)
Morbidity:
  - Congenital anomalies

Newborn Outcomes
Mortality:
  - Neonatal mortality (deaths between 0 and 28 days)
Morbidity:
  - Preterm birth (<37 weeks gestation)
  - Small-for-gestational age (defined by study authors)
  - Macrosomia (birthweight >4000 g)
Anthropometry:
  - Birthweight (g)
  - Birth length (cm)
  - Head circumference (cm)

Child Outcomes
Mortality:
  - Infant mortality (deaths between 0 and 12 months)
  - Under-five mortality (deaths between 0 and 59 months)
Morbidity:
  - Stunting (-2 z-score or lower)
  - Wasting (-2 z-score or lower)
  - Underweight (-2 z-score or lower)
  - Bone mineral density
  - Fracture
  - Rickets
  - Hypothyroidism or elevated thyroid stimulating hormone (TSH)
  - Development outcomes (as defined by study authors)
  - Infection
  - Respiratory disease
  - Allergic disease
Biochemical status:
  - Micronutrient deficiencies
    - Vitamin A (serum/plasma retinol)
    - Iron (serum/plasma ferritin, plasma TfR)
    - Serum/plasma/red blood cell folate
    - Serum/plasma zinc
    - Serum/plasma vitamin D (25-hydroxyvitamin D)
  - Anaemia
    - Hemoglobin concentration
  - Iron deficiency anaemia
Other Outcomes

- Relevant long-term outcomes during adolescence or adulthood, as specified by trial authors. For example:
  - Anthropometrics (stunting, wasting, underweight)
  - Cognitive and motor development, as assessed by trialists (e.g. Bayley Mental Development Index, Bayley Psychomotor Development Index, Stanford-Binet test)
  - Educational attainment (completion of primary or secondary school)
- Mode of delivery (vaginal, instrumental vaginal, caesarean)
- Adverse outcomes: any reported throughout intervention period (e.g. urinary tract infections, kidney stones, hyperthyroidism, allergic reactions, etc.), including short-term adverse outcomes (e.g. vomiting, abdominal pain, constipation, diarrhea, unpleasant tastes)

Study designs

We will include primary studies, including large-scale programme evaluations, which assess the efficacy and/or effectiveness of interventions using experimental and quasi-experimental study designs that allow for causal inference:

1. Studies where participants were randomly assigned, individually or in clusters, to intervention and comparison groups.

2. Studies where non-random assignment to intervention and comparison groups is based on other known allocation rules, including a threshold on a continuous variable (regression discontinuity designs) or exogenous geographical variation in the treatment allocation (natural experiments).

3. Controlled before-after studies in which allocation to intervention and control groups was not made by study investigators, and outcomes were measured in both intervention and control groups at baseline, and appropriate methods were used to control for selection bias and confounding, such as statistical matching (e.g., propensity score matching, or covariate matching) or regression adjustment (e.g., difference-in-differences, instrumental variables).

4. Interrupted time series studies in which outcomes were measured in the intervention group at least three time points before the intervention was implemented and at least three time points after.

References


# Review authors

## Lead review author:

<table>
<thead>
<tr>
<th>Name:</th>
<th>Emily C. Keats</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title:</td>
<td>Research Associate</td>
</tr>
<tr>
<td>Affiliation:</td>
<td>Centre for Global Child Health, The Hospital for Sick Children</td>
</tr>
<tr>
<td>Address:</td>
<td>686 Bay Street, 11th Floor</td>
</tr>
<tr>
<td>City, Province or County:</td>
<td>Toronto, Ontario</td>
</tr>
<tr>
<td>Post code:</td>
<td>M5G 0A4</td>
</tr>
<tr>
<td>Country:</td>
<td>Canada</td>
</tr>
<tr>
<td>Phone:</td>
<td>+1.416.813.7654</td>
</tr>
<tr>
<td>Email:</td>
<td><a href="mailto:emily.keats@sickkids.ca">emily.keats@sickkids.ca</a></td>
</tr>
</tbody>
</table>

## Co-authors:

<table>
<thead>
<tr>
<th>Name:</th>
<th>Aamer Imdad</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title:</td>
<td>Assistant Professor of Pediatrics</td>
</tr>
<tr>
<td>Affiliation:</td>
<td>State University of New York Upstate Medical University</td>
</tr>
<tr>
<td>Address:</td>
<td>Suite 504, 725 Irving Ave</td>
</tr>
<tr>
<td>City, Province or County:</td>
<td>Syracuse, NY</td>
</tr>
<tr>
<td>Post code:</td>
<td>13210</td>
</tr>
<tr>
<td>Country:</td>
<td>USA</td>
</tr>
<tr>
<td>Phone:</td>
<td>+1.315.447.5407</td>
</tr>
<tr>
<td>Email:</td>
<td><a href="mailto:aamer08@gmail.com">aamer08@gmail.com</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Zulfiqar A. Bhutta</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title:</td>
<td>Co-Director, Centre for Global Child Health</td>
</tr>
<tr>
<td>Affiliation:</td>
<td>The Hospital for Sick Children</td>
</tr>
<tr>
<td>Address:</td>
<td>686 Bay Street, 11th Floor</td>
</tr>
<tr>
<td>City, Province or County:</td>
<td>Toronto, Ontario</td>
</tr>
<tr>
<td>Post code:</td>
<td>M5G 0A4</td>
</tr>
<tr>
<td>Country:</td>
<td>Canada</td>
</tr>
<tr>
<td>Phone:</td>
<td>+1.416.813.7654</td>
</tr>
<tr>
<td>Email:</td>
<td><a href="mailto:zulfiqar.bhutta@sickkids.ca">zulfiqar.bhutta@sickkids.ca</a></td>
</tr>
</tbody>
</table>
Roles and responsibilities

Emily Keats and Aamer Imdad have methodological, statistical, and information retrieval expertise. Zulfiqar Bhutta has content expertise. All additional team members (to be determined) will receive training in systematic review methods.

Funding

Funding for this review came from a grant from the Bill & Melinda Gates Foundation to the Centre for Global Child Health at the Hospital for Sick Children (Grant No. OPP1137750).

Potential conflicts of interest

The authors are not aware of any conflicts of interest arising from financial or researcher interests.

Preliminary timeframe

- Date we plan to submit a draft protocol: 30 January 2018
- Date we plan to submit a draft review: 30 June 2018